Reference ID: 4212951 - Genentech
3 Table 2. Recommended Dose Modifications for COTELLIC for Adverse Reactions Severity of Adverse Reactiona Dose Modification for COTELLIC New Primary Malignancies (cutaneous and non-cutaneous)
Download Reference ID: 4212951 - Genentech
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.gene.com1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for
Initial dose of 4 mg/kg over 90 minute IV infusion, …
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
www.gene.com2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …
HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …
www.gene.comfull prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive
OCREVUS Prescribing Information - Genentech
www.gene.comHepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …
www.gene.com162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg
XOLAIR Prescribing Information - Genentech
www.gene.comCorticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)
XOFLUZA Prescribing Information - Genentech
www.gene.comHypersensitivitysuch as anaphylaxis, angioedema,urticaria,and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. (5.1) Risk of bacterial infection:Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as,a complication of influenza.
Related documents
Comparison of Completely versus Incompletely …
annals.edu.sg68 Annals Academy of Medicine Incompletely Excised SCCs—P Ang et al Comparison of Completely versus Incompletely Excised Cutaneous Squamous Cell Carcinomas
MULTIPLE MYELOMA (MM) - Celgene
media.celgene.comArea of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr LYMPHOMA REVLIMID® (lenalidomide) Mantle cell lymphoma: Relapsed/refractory . . . . . . . . . . Diffuse large B-cell lymphoma (ABC subtype): First-line .
British Association of Dermatologists' guidelines for …
www.bad.org.ukimplementation in the National Health Service using a process of considered judgement based on the evidence. PubMed and the Medline …
LCA Skin Cancer Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA SKIN CANCER CLINICAL GUIDELINES 4 Introduction and Background The National Institute for Health and Care Excellence (NICE) published Improving Outcomes for People with Skin Tumours including Melanoma1 in 2006 (Improving Outcomes Guidance – IOG2) as part of the review of all tumour types, to implement The NHS Cancer Plan. The …
Reference ID: 3101735 - Food and Drug …
www.accessdata.fda.gov3 5.1 . FULL PRESCRIBING INFORMATION: CONTENTS* WARNING 1 INDICATIONS AND USAGE . 1.1 . Breast Cancer 1.2 . Non-Small Cell …